Aura Biosciences, Inc. (NASDAQ:AURA) SVP Amy Elazzouzi Sells 7,722 Shares

Key Points

• Amy Elazzouzi, SVP of Aura Biosciences, sold 7,722 shares at an average price of $6.70, reducing her stake by 8.19% and leaving 86,558 shares valued at $579,938.60.
• Aura Biosciences reported an EPS of ($0.47) for the last quarter, surpassing analyst expectations of ($0.49).
• Wall Street analysts maintain a positive outlook with an average rating of "Buy" and a consensus target price of $22.00.

Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) SVP Amy Elazzouzi sold 7,722 shares of the company's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $6.70, for a total value of $51,737.40. Following the completion of the transaction, the senior vice president directly owned 86,558 shares of the company's stock, valued at $579,938.60. The trade was a 8.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Aura Biosciences Stock Down 0.4%

Shares of Aura Biosciences stock traded down $0.03 during mid-day trading on Monday, reaching $6.69. 154,768 shares of the stock traded hands, compared to its average volume of 219,353. Aura Biosciences, Inc. has a fifty-two week low of $4.34 and a fifty-two week high of $12.38. The stock has a market capitalization of $415.58 million, a PE ratio of -3.41 and a beta of 0.46. The business has a 50-day moving average of $6.62 and a 200 day moving average of $6.51.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. On average, equities research analysts expect that Aura Biosciences, Inc. will post -1.66 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. HC Wainwright reaffirmed a "buy" rating and issued a $22.00 price target on shares of Aura Biosciences in a report on Wednesday, August 13th. JMP Securities reaffirmed a "market outperform" rating and issued a $19.00 price target on shares of Aura Biosciences in a report on Friday, May 23rd. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $22.00.

Institutional Investors Weigh In On Aura Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC increased its holdings in shares of Aura Biosciences by 49.3% in the second quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company's stock valued at $40,000 after purchasing an additional 2,104 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in shares of Aura Biosciences in the fourth quarter valued at approximately $50,000. GAMMA Investing LLC increased its holdings in shares of Aura Biosciences by 5,766.9% in the first quarter. GAMMA Investing LLC now owns 9,739 shares of the company's stock valued at $57,000 after purchasing an additional 9,573 shares during the last quarter. Invesco Ltd. acquired a new stake in shares of Aura Biosciences in the second quarter valued at approximately $76,000. Finally, Bridgeway Capital Management LLC acquired a new stake in shares of Aura Biosciences in the second quarter valued at approximately $102,000. Institutional investors and hedge funds own 96.75% of the company's stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.